AOD 9604 (5mg)

What is AOD 9604 (5mg)?

AOD 9604 (5 mg) is a synthetic research peptide used in studies of weight regulation and metabolic function. It is a 16–amino-acid fragment from the C-terminal region of human growth hormone (often referenced as hGH 177–191 or Tyr-hGH 177–191). Because this region has been linked to fat metabolism in research models, it is sometimes described as part of a “lipolytic domain.”

In laboratory settings, AOD 9604 is used to explore how growth hormone–derived fragments may influence fat breakdown, fat storage, and energy use in cell-based systems and non-clinical animal models—without the broader hormonal activity of full-length growth hormone.

Product Specifications

• CAS Number: 221231‑10‑3​
• Peptide Sequence: Tyr‑Leu‑Arg‑Ile‑Val‑Gln‑Cys‑Arg‑Ser‑Val‑Glu‑Gly‑Ser‑Cys‑Gly‑Phe‑OH​
• Molecular Weight: 1815.10 g/mol​
• Chemical Formula: C₇₈H₁₂₃N₂₃O₂₃S₂​
• Purity: ≥99% (HPLC)​
• Packaging Format: 5 mg lyophilized powder in a research‑grade glass vial
• Storage Conditions (unreconstituted): Store at −20 °C, avoid light exposure; keep container tightly closed
• Intended Use: For laboratory research use only; not for human or veterinary use

Key Characteristics of AOD 9604 (5mg)

• Defined GH fragment: A 16–amino-acid segment from human growth hormone used to study metabolism-related effects in research models.
• Metabolic research focus: Examined in obese rodent studies for changes in weight gain patterns, fat oxidation, and markers associated with lipolysis and lipogenesis.
• Limited human evidence: Human studies have mainly evaluated safety and metabolic markers; weight outcomes were modest and inconsistent, and development for obesity treatment was not continued.
• Different from full-length GH (experimental): Research suggests minimal effect on IGF-1 and limited activation of classical growth hormone receptor signaling compared with intact GH.
• Pathway-level interest: Used to investigate mechanisms involved in cellular energy balance and lipid handling in controlled models.
• Research-grade format: High-purity, lyophilized material designed to support reproducibility in non-clinical metabolic studies.
• Standard lab handling: Requires routine peptide precautions, including aseptic technique, PPE, and controlled storage.

How AOD 9604 (5mg) Supports Research

AOD 9604 (5mg) is a research tool, not a treatment. It allows researchers to study how parts of human growth hormone can affect fat and energy metabolism, without the full hormone’s effects.

In rodent studies, AOD 9604 has been used to examine its effects on weight gain, fat burning, and fat breakdown and storage.

In lab experiments with cells and tissues, AOD 9604 is used to explore how fat cells respond to this growth hormone fragment, including changes in enzyme activity, gene expression, and energy-related signaling pathways.

Human studies have mainly focused on safety, how the body handles the peptide, and metabolic markers such as IGF-1 and glucose levels, but have not shown strong evidence of weight loss. So, AOD 9604 should be viewed as a tool for studying metabolism, not as a weight loss treatment.

Research Applications & Usage Information

In laboratory research, AOD 9604 (5mg) can be used in various studies aimed at understanding fat and energy metabolism. Common applications include:

• Obesity and Body-Weight Regulation Models: Studying how chronic exposure to AOD 9604 affects body weight, fat, and energy use in obese rodents, often using calorimetry (measuring energy expenditure) and body fat measurements.
• Adipocyte Biology and Fat-Cell Function: Investigating how AOD 9604 influences fat breakdown (lipolysis) and fat storage (lipogenesis) in isolated fat tissue or cultured fat cells. This includes measuring glycerol and free fatty acids as indicators of fat metabolism.
• Pathway-Level Metabolic Research: Examining how AOD 9604 affects pathways linked to fat and energy regulation, like β-adrenergic and AMPK pathways, to understand how this peptide influences energy use in cells.
• Comparative Growth Hormone Fragment Studies: Comparing AOD 9604 with full-length human growth hormone and other growth hormone fragments to find out which parts of the hormone are responsible for specific metabolic effects.
• Safety, Pharmacology, and Regulatory Science: Studying how AOD 9604 is absorbed, distributed, metabolized, and excreted in the body, as well as comparing its safety profile with that of full-length growth hormone.

Researchers determine the specific conditions of each experiment, including peptide concentrations, exposure times, and study protocols, based on their research goals and institutional guidelines. No dosing or regimen recommendations are provided or implied for human or veterinary use.

Handling and Storage Recommendations

To preserve the quality of the product and support safe laboratory practices, follow these guidelines:

• Store at −20 °C or below.
• Keep sealed and protected from light.
• Reduce freeze–thaw cycling.
• Allow room temperature only for transport/handling.

Research Use Only Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Stier H. Safety and tolerability of the hexadecapeptide AOD9604 in humans. Journal of Endocrinology and Metabolism. Published online April 23, 2013. doi:10.4021/JEM.V3I1-2.157
2. Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. doi:10.1210/endo.142.12.8522
3. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. doi:10.1159/000053183
4. Heffernan MA, Thorburn AW, Fam B, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449. doi:10.1038/sj.ijo.0801740